-
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 stud
Author: Pistilli, B.; Jhaveri, K.; Im, S. -a.; Pernas, S.; De Laurentiis, M.; Wang, S.; Janez, N. Martinez; Borges, G.; Cescon, D. W.; Hattori, M.; Lu, Y. -s.; Hamilton, E.; Tsurutani, J.; Kalinsky, K.; Liedke, P. E. Rubini; Carroll, D.; Khan, S.; Rugo, H. S.; Xu, B.; Bardia, A
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 5, pp. 663-674. DOI: 10.1016/j.annonc.2025.12.017
-
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 tria
Author: Schmid, P.; McArthur, H. L.; Cortes, J.; Xu, B.; Cardoso, F.; Casalnuovo, M.; Demirci, U.; Freitas-Junior, R.; Ghosh, J.; Hegg, R.; Iwata, H.; Karnaukhov, I.; Chuken, Y. L.; Nechaeva, M.; Robson, M. E.; Villalobos-Valencia, R.; Yamashita, T.; Zurawski, B.; de Bruin, E. C.; Grinsted, L.; D'Cruz, C.; Foxley, A.; Park, Y. H
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 5, pp. 650-662. DOI: 10.1016/j.annonc.2025.12.012
-
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 tria
Author: Wang, C.; Wang, W.; Liu, H.; Chen, Q.; Chen, C.; Liu, L.; Zhang, P.; Zhao, G.; Yang, F.; Han, G.; Yu, B.; Yang, Y.; Chen, H.; Jiang, J.; Tan, L.; Xu, S.; Mao, N.; Hu, J.; Zhang, L.; Zhang, Z.; Yao, B.; Wang, S.; Leaw, S.; Naicker, K.; Zheng, W.; Yu, C.; Yue, D
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 4, pp. 544-554. DOI: 10.1016/j.annonc.2025.11.017
-
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 tria
Author: Jhaveri, K. L.; Neven, P.; Casalnuovo, M. L.; Kim, S. -b.; Tokunaga, E.; Aftimos, P.; Saura, C.; O'shaughnessy, J.; Harbeck, N.; Carey, L. A.; Curigliano, G.; Watanabe, J.; Lim, E.; Huang, J.; Qingyuan, Z.; Llombart-Cussac, A.; Huang, C.; Desai, B.; Wang, X. A.; Cao, S.; Bidard, F. C
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 4, pp. 532-543. DOI: 10.1016/j.annonc.2025.11.018
-
Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort stud
Author: Toss, A.; Blondeaux, E.; Tenedini, E.; Bonamici, L.; Graffeo, R.; Livraghi, L.; Villarreal-Garza, C.; Molho, R. Bernstein; Kwong, A.; Balmana, J.; Wildiers, H.; Agostinetto, E.; Phillips, K. A.; Pogoda, K.; Renaud, T.; Rousset-Jablonski, C.; Ferrari, A.; Moore, H. C. F.; Peccatori, F. A.; Paluch-Shimon, S.; Fruscio, R.; Micheri, C.; Wong, S. M.; Cui, W.; Vernieri, C.; Lee, M. K.; De Marchis, L.; Couch, F. J.; Del Mastro, L.; Puglisi, F.; Meireles, P. A.; Kemp, Z.; Matikas, A.; Plichta, J.; Del Pilar Estevez-Diz, M.; Di Meglio, A.; Cichowska-Cwalinska, N.; Gianni, C.; Yerushalmi, R.; Sanchez-Bayona, R.; Mrinakova, B.; Matos, L.; Bianchini, G.; Caleffi, M.; Krivokuca, A.; Abdou, Y.; Marino-Marino, M.; Parokonnaya, A.; Okano, M.; Antone, N.; Saavedra, C.; Sonnenblick, A.; Duchnowska, R.; Pais, H. L.; Harbeck, N.; Cortesi, L.; Delucchi, V.; De Angelis, C.; Lambertini, M
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 3, pp. 364-377. DOI: 10.1016/j.annonc.2025.11.004
-
Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinom
Author: Wang, Y.; Rosell, R.; Hirsch, F. R.; Lu, S.; Govindan, R.; Park, K.; Peters, S.; Zhang, J. J
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 3, pp. 289-313. DOI: 10.1016/j.annonc.2025.11.008
-
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitor
Author: Zhu, Y.; Jiang, S.; Shi, Y.; Wang, S.; Yuan, F.; Zhou, F.; Jiang, K.; Zhang, X.; Seneviratne, L.; Yu, G.; Zhang, M.; Liu, T.; Li, X.; Chen, X.; Wang, X.; Zhang, S.; Liu, Y.; Ge, Y.; Chen, M.; Blumenthal, G.; Akala, O.; Li, Y.; Ge, J.; Ye, D
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 3, pp. 378-387. DOI: 10.1016/j.annonc.2025.11.013
-
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-0
Author: Hurvitz, S. A.; Loi, S.; O'shaughnessy, J.; Okines, A. F. C.; Tolaney, S. M.; Sohn, J.; Saura, C.; Zhu, X.; Cameron, D.; Bachelot, T.; Hamilton, E.; Curigliano, G.; Wolff, A. C.; Harbeck, N.; Masuda, N.; Vahdat, L.; Zaman, K.; Valdes-Albini, F.; Block, M.; Pluard, T.; Tan, T. J.; Gawryletz, C.; Chan, A.; Bedard, P. L.; Yerushalmi, R.; Xu, B.; Schmitt, M.; Xie, D.; Borges, V. F
Journal: ANNALS OF ONCOLOGY. 2026; Vol. 37, Issue 3, pp. 341-352. DOI: 10.1016/j.annonc.2025.11.005
